Resistance to RAF inhibitors revisited
In early 2011, we reviewed the initial success of the RAF inhibitor, vemurafenib, in mutant V600 BRAF melanoma patients. It was soon evident that the response to RAF inhibitor is heterogeneous and that the short-term benefits are burdened by the development of resistance. The field has progressed ra...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947111/ |